证券代码：301559 证券简称：中集环科 公告编号：2025-015 中集安瑞环科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 中集安瑞环科技股份有限公司（以下简称"公司"）2024 年年度利润分配方 案已获公司 2024 年年度股东会审议通过。现将有关情况公告如下： 一、股东会审议通过利润分配情况 1、公司于 2025 年 4 月 14 日召开 2024 年年度股东会审议通过了《关于 2024 年度利润分配预案的议案》，同意公司 2024 年度利润分配预案如下： 以截至 2024 年 12 月 31 日公司总股本 60,000 万股为基数，向全体股东每 10 股派发现金红利 4.4 元（含税），合计派发现金红利 2.64 亿元人民币（含税）， 不送红股，不以资本公积金转增股本，剩余未分配利润结转至以后年度。 2024 年度公司预计现金分红总额为 2.64 亿元（含税），占 2024 年度公司实 现归属于上市公司股东的净利润的 86.88%。 按照《公司法》和《公司章程》规定，公司不存在需要弥补亏损、提取任 ...

Group 1: Company Overview - CIMC Enric is a subsidiary of CIMC Group, primarily engaged in the design, research and development, manufacturing, and sales of tank containers, making it a global leader in liquid and liquefied gas container logistics equipment manufacturing and lifecycle services [1] - The company also has a medical equipment components business [1] Group 2: Financial Performance - In Q1 2025, the company achieved a revenue of CNY 611.23 million, a decrease of 1.31% compared to the same period last year [2] - Revenue breakdown: - Tank container revenue: CNY 480.76 million, down 2.57% year-on-year - Medical equipment components revenue: CNY 54.41 million, up 20.98% year-on-year - Aftermarket business revenue: CNY 36.08 million, up 0.15% year-on-year [2] - The company reported a net profit of CNY 22.02 million in Q1 2025, a decline attributed to intensified competition, changes in product structure, and exchange rate fluctuations [3] Group 3: Market Outlook and Orders - The company anticipates challenges in 2025 due to geopolitical uncertainties and new trade policies affecting global economic recovery [2] - In Q1 2025, new orders totaled CNY 444 million, a year-on-year increase of 17.27% - As of March 31, 2025, the backlog of orders was CNY 791 million, a decrease of 17.87% compared to the same period last year [2] Group 4: Future Plans and Dividends - The company plans to expand its medical equipment components business, focusing on product range and scale through increased R&D and investment [3] - A dividend plan for 2024-2026 has been established, proposing a cash dividend of CNY 4.40 per 10 shares, with a total distribution of CNY 264 million based on a total share capital of 600 million shares as of December 31, 2024 [4]

Investment Rating - The report maintains an "Accumulate" rating for the company [8] Core Views - The company reported Q1 2025 revenue of 611 million RMB, a year-over-year decrease of 1.31% and a quarter-over-quarter decrease of 38.57%. The net profit attributable to the parent company was 22 million RMB, down 56.99% year-over-year and 81.92% quarter-over-quarter. The company signed new orders worth 444 million RMB in Q1 2025, representing a year-over-year increase of 17.27% [1][2] - Despite short-term challenges in the tank container industry due to macroeconomic uncertainties, the company is expected to leverage its scale and brand advantages to enhance cost control and increase market share [1][4] - The company's gross margin in Q1 2025 was 14.56%, a decrease of 2.76 percentage points year-over-year and 1.84 percentage points quarter-over-quarter, primarily due to short-term demand pressure in the downstream chemical industry and intensified competition [3] Summary by Sections Financial Performance - In Q1 2025, the tank container business generated revenue of 481 million RMB, down 2.57% year-over-year, while the medical equipment components business saw revenue growth of 20.98% to 54 million RMB. The aftermarket business revenue was 36 million RMB, a slight increase of 0.15% year-over-year [2] - The company plans to increase product innovation in tank containers and strengthen manufacturing cost control to further enhance market share [4] Profitability and Costs - The company's expense ratio in Q1 2025 was 8.09%, an increase of 4.73 percentage points year-over-year and 8.72 percentage points quarter-over-quarter. The financial expense ratio was -1.00%, reflecting an increase of 5.11 percentage points year-over-year, mainly due to increased foreign exchange losses [3] Market Outlook - The long-term outlook for the tank container industry remains positive despite short-term challenges. The company, as a market leader with approximately 50% market share, is expected to benefit from the rapid development of multimodal transport and stricter environmental regulations [4] Earnings Forecast and Valuation - The company’s projected net profits for 2025-2027 are 445 million RMB, 543 million RMB, and 609 million RMB, respectively. The target price is set at 19.94 RMB, based on a 2.4 times price-to-book (PB) ratio for 2025 [5][9]

Core Viewpoint - The company, CIMC Enric Holdings Co., Ltd. (中集环科), reported strong financial performance in Q1 2025, with significant growth in new orders and a focus on high-quality development and green initiatives [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 611 million yuan, net profit attributable to shareholders of 22.38 million yuan, and net cash flow from operating activities of 171 million yuan [1]. - The total new orders signed in the first three months amounted to 444 million yuan, representing a year-on-year increase of 17.27% [1][2]. - As of March 31, 2025, the company had a backlog of orders totaling 791 million yuan [1]. Strategic Initiatives - The company adheres to a development strategy focused on "lean innovation, intelligent transformation, global connectivity, and green development" [1][2]. - In 2024, the company emphasized smart and green development, enhancing its technological research and development, intelligent upgrades, and lean management [1]. - The "flexible green intelligent factory" project was recognized as one of the first batch of excellent intelligent factories by the Ministry of Industry and Information Technology [1]. Green Development Efforts - The company promotes green practices across production, logistics, and process control, including the introduction of solar photovoltaic facilities and the replacement of traditional painting processes with powder coating [2]. - It has been awarded the title of "National Green Factory for 2024" by the Ministry of Industry and Information Technology, reflecting its commitment to reducing environmental impact while enhancing product value [2]. - The focus on green and intelligent development has led to improved product competitiveness and increased recognition among global customers [2].

Core Viewpoint - Company reported a slight decline in overall revenue for Q1 2025, but the medical device components business showed significant growth, indicating a strategic shift towards higher value-added products [1][2]. Group 1: Financial Performance - Company achieved operating revenue of 611.23 million yuan in Q1 2025, a decrease of 1.31% compared to the same period last year [1]. - Revenue from tank containers was 480.76 million yuan, down 2.57% year-on-year [1]. - Medical device components revenue reached 54.41 million yuan, marking a 20.98% increase year-on-year [1]. - Aftermarket business revenue was 36.08 million yuan, with a slight increase of 0.15% year-on-year [1]. Group 2: Business Segment Growth - The medical device components business accounted for 8.90% of total revenue in Q1 2025, up from 7.19% in 2024 [1]. - The company has developed high-end medical imaging equipment components, particularly for MRI machines, gaining recognition from industry leaders [1]. Group 3: Market Trends and Strategic Positioning - The growth in the medical device components business aligns with global trends such as aging populations and increasing health awareness, driving demand for high-end medical equipment [2]. - The Chinese government has initiated policies to enhance medical service levels, which is expected to boost the market for MRI machines and related equipment [2]. - The domestic medical imaging equipment market is projected to grow from 53.7 billion yuan in 2020 to nearly 110 billion yuan by 2030, with a compound annual growth rate of 7.3% [2]. Group 4: Future Outlook - Despite the current low revenue contribution from the medical device components business, its strategic value and performance contribution are expected to increase as the downstream medical imaging market continues to grow [3].

Financial Performance - The company reported a basic earnings per share of 0.0400 yuan for Q1 2025, a decrease of 55.56% compared to 0.0900 yuan in Q1 2024 and a significant drop from 0.4400 yuan in Q1 2023 [1] - The net profit for Q1 2025 was 0.22 billion yuan, down 57.69% from 0.52 billion yuan in Q1 2024 and a sharp decline from 2.23 billion yuan in Q1 2023 [1] - The operating revenue for Q1 2025 was 6.11 billion yuan, a decrease of 1.29% from 6.19 billion yuan in Q1 2024 and a substantial drop from 14.19 billion yuan in Q1 2023 [1] - The return on equity (ROE) for Q1 2025 was 0.47%, down 57.66% from 1.11% in Q1 2024 and a significant decline from 8.46% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 6.8026 million shares, accounting for 7.56% of the circulating shares, with an increase of 1.9709 million shares compared to the previous period [1] - Notable new shareholders include Ji Zihao with 1.8455 million shares (2.05% of total shares) and Zhi Yuan 38 single asset management plan with 0.3420 million shares (0.38% of total shares) [2] - Hong Kong Central Clearing Limited increased its holdings by 64.18% to 1.4181 million shares (1.58% of total shares) [2] Dividend Policy - The company has decided not to distribute dividends or bonus shares this time [3]

Financial Performance - The company's revenue for Q1 2025 was ¥611,226,370.64, a decrease of 1.31% compared to ¥619,358,847.22 in the same period last year[5] - Net profit attributable to shareholders was ¥22,377,960.10, down 56.99% from ¥52,033,709.00 year-on-year[5] - Basic and diluted earnings per share decreased by 55.56%, from ¥0.09 to ¥0.04[5] - Total operating revenue for the current period was CNY 611,226,370.64, a decrease of 1.83% from CNY 619,358,847.22 in the previous period[19] - Net profit for the current period was CNY 22,024,814.61, down 56.5% from CNY 50,642,603.28 in the previous period[20] Cash Flow and Investments - The net cash flow from operating activities increased by 111.16%, reaching ¥170,778,264.47, compared to ¥80,875,988.23 in the previous year[5] - Operating cash inflow for the current period was $730,450,826.53, an increase from $690,789,911.89 in the previous period, representing a growth of approximately 8.5%[22] - Net cash flow from investment activities was $1,102,276,233.40, a significant improvement from a negative $33,219,921.10 in the prior period[22] - The net increase in cash and cash equivalents for the current period was $1,263,075,715.54, a notable rise from $49,755,356.69 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,503,522,621.61, reflecting a 0.93% increase from ¥5,452,806,845.37 at the end of the previous year[5] - Total liabilities increased to CNY 773,330,261.08 from CNY 749,516,475.76, indicating a rise of 3.4%[18] - The total equity attributable to shareholders of the parent company was CNY 4,732,729,228.87, up from CNY 4,705,498,614.70 in the previous period[18] Revenue Segmentation - The revenue from tank containers was CNY 480.76 million, down 2.57% year-on-year, while revenue from medical device components increased by 20.98% to CNY 54.41 million[13] - The company signed new orders totaling CNY 444 million in Q1 2025, representing a growth of 17.27% year-on-year[13] - As of March 31, 2025, the company's backlog of orders was CNY 791 million, a decrease of 17.87% year-on-year[13] Other Financial Metrics - The company reported a significant increase in other comprehensive income, which rose by 1371.23% due to foreign currency translation adjustments[9] - Tax expenses decreased by 62.50% due to a reduction in total profit[9] - The company’s investment income increased by 33.98%, driven by favorable foreign exchange movements[9] - The company’s financial expenses rose by 83.89%, primarily due to increased foreign exchange losses[9] - Research and development expenses were CNY 21,989,054.00, slightly up from CNY 21,387,680.72 in the previous period[19] - The company recorded a fair value gain of CNY 13,054,000.00, compared to a loss of CNY 4,111,700.00 in the previous period[19] - Other comprehensive income after tax for the current period was CNY 2,345,511.48, compared to CNY 336,526.50 in the previous period[20] Market Position and Strategy - The company maintained its market position in the tank container business while experiencing steady growth in the medical device components segment[12] - The company approved the use of self-owned foreign exchange to pay for fundraising projects, allowing for the replacement of equivalent funds from the fundraising account[14] - The company also approved the completion of certain fundraising projects and the permanent allocation of surplus funds to working capital[14] Audit Status - The company’s first quarter report was not audited, indicating a preliminary financial assessment[24]

投资者关 系活动类 别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ☑其他 _电话会议__ 活动参与 人员 鼎晖股权投资管理（天津）有限公司 尹竟行、刘穗、黄弘翰、吕牧泉、夏宇轩 公司董事、总裁 季国祥 公司副总裁、首席财务官兼董事会秘书 张 毅 公司董事会办公室主任 王延民 时间 2025 年 4 月 15 日 地点 中集环科公司 形式 □现场 □网上 ☑电话会议 交流内容 及具体问 答记录 问题 1：请介绍目前业务部门的业务范围，对应的收入、盈利规模，人员 情况。 答：公司主要从事罐式集装箱行业的设计研发、生产制造和销售，是全球 领先的液体、液化气体（常温）集装箱化物流装备制造企业和全生命周期服务 商，并衍生出医疗设备部件业务。 2024 年，公司实现营业收入 334,909.30 万元，其中：罐式集装箱营业收 入 274,834.64 万元；医疗设备部件营业收入 24,092.41 万元；后市场业务营 业收入 14,723.08 万元。2024 年，公司归母净利润 30,387.02 万元。 2024 年，公司在职员工数量合计 2256 人。 问题 2： ...

北京市金杜律师事务所上海分所 关于中集安瑞环科技股份有限公司 2024 年年度股东会之法律意见书 致：中集安瑞环科技股份有限公司 北京市金杜律师事务所上海分所（以下简称本所）接受中集安瑞环科技股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委 员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内 （以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中 国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章和规范性 文件和现行有效的《中集安瑞环科技股份有限公司章程》（以下简称《公司章程》） 有关规定，指派律师出席了公司于 2025 年 4 月 14 日召开的 2024 年年度股东 会（以下简称本次股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年第二次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 22 日刊登于巨潮资讯网及深圳证券交易所（以下 ...

证券代码：301559 证券简称：中集环科 公告编号：2025-013 中集安瑞环科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形。 2、本次股东会不涉及变更以往股东会已通过决议的情形。 一、会议召开及出席情况 通过深圳证券交易所（以下简称"深交所"）交易系统投票的时间为 2025 年 4 月 14 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深交所互联网投票系统 投票的时间为 2025 年 4 月 14 日 9:15-15:00。 2、召开地点：江苏省南通市城港路 159 号中集安瑞环科技股份有限公司 301 会议室 3、召开方式：本次股东会采取现场投票与网络投票相结合的方式。 4、召集人：公司董事会 5、主持人：董事长杨晓虎先生 （一）会议召开情况 1、召开时间： （1）现场会议召开时间：2025 年 4 月 14 日（星期一）下午 14:30 （2）网络投票时间：2025 年 4 月 14 日 3、公司董事、监事、高级管理人员 ...